Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Indian J Public Health ; 64(Supplement): S125-S127, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: covidwho-538987


Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). India has approved the use of HCQ for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration has issued Emergency Use Authorization for the use of HCQ to treat COVID-19 in adolescents and adults. In this review, we go over the available evidence for and against HCQ's use as prophylaxis or treatment for COVID-19, especially in the Indian context.

Antimaláricos/uso terapéutico , Infecciones por Coronavirus/tratamiento farmacológico , Hidroxicloroquina/uso terapéutico , Neumonía Viral/tratamiento farmacológico , Antibacterianos/uso terapéutico , Antimaláricos/administración & dosificación , Antimaláricos/efectos adversos , Azitromicina/uso terapéutico , Betacoronavirus , Quimioterapia Combinada , Humanos , Hidroxicloroquina/administración & dosificación , Hidroxicloroquina/efectos adversos , Pandemias
Emerg Microbes Infect ; 9(1): 830-832, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: covidwho-125318


The current pandemic coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls urgently for effective therapies. Anti-malarial medicine chloroquine (CQ) and particularly its chemical analogue hydroxychloroquine (HCQ) have been recommended as promising candidate therapeutics that are now under either compassionate off-label use or clinical trials for the treatment of COVID-19 patients. However, there are public concerns and disputes about both the safety and efficacy of CQ and HCQ for this new application. Given the fact that for decades HCQ has been approved as an immunomodulatory drug for the long term treatment of chronic rheumatic diseases, as experienced rheumatologists, we would like to share our thoughts in this regard and trigger a brainstorm among clinical care providers for exchanging their diverse opinions on this urgent topic.

Antimaláricos , Antirreumáticos , Antivirales , Betacoronavirus/efectos de los fármacos , Infecciones por Coronavirus/tratamiento farmacológico , Hidroxicloroquina , Neumonía Viral/tratamiento farmacológico , Antimaláricos/administración & dosificación , Antimaláricos/efectos adversos , Antimaláricos/uso terapéutico , Antirreumáticos/administración & dosificación , Antirreumáticos/efectos adversos , Antirreumáticos/uso terapéutico , Antivirales/administración & dosificación , Antivirales/efectos adversos , Antivirales/uso terapéutico , Ensayos Clínicos como Asunto , Infecciones por Coronavirus/epidemiología , Humanos , Hidroxicloroquina/administración & dosificación , Hidroxicloroquina/efectos adversos , Hidroxicloroquina/uso terapéutico , Comunicación Interdisciplinaria , Pandemias , Neumonía Viral/epidemiología , Reumatólogos
J Crit Care ; 57: 279-283, 2020 06.
Artículo en Inglés | MEDLINE | ID: covidwho-6364


PURPOSE: COVID-19 (coronavirus disease 2019) is a public health emergency of international concern. As of this time, there is no known effective pharmaceutical treatment, although it is much needed for patient contracting the severe form of the disease. The aim of this systematic review was to summarize the evidence regarding chloroquine for the treatment of COVID-19. METHODS: PubMed, EMBASE, and three trial Registries were searched for studies on the use of chloroquine in patients with COVID-19. RESULTS: We included six articles (one narrative letter, one in-vitro study, one editorial, expert consensus paper, two national guideline documents) and 23 ongoing clinical trials in China. Chloroquine seems to be effective in limiting the replication of SARS-CoV-2 (virus causing COVID-19) in vitro. CONCLUSIONS: There is rationale, pre-clinical evidence of effectiveness and evidence of safety from long-time clinical use for other indications to justify clinical research on chloroquine in patients with COVID-19. However, clinical use should either adhere to the Monitored Emergency Use of Unregistered Interventions (MEURI) framework or be ethically approved as a trial as stated by the World Health Organization. Safety data and data from high-quality clinical trials are urgently needed.

Antimaláricos , Betacoronavirus , Cloroquina , Infecciones por Coronavirus/tratamiento farmacológico , Neumonía Viral/tratamiento farmacológico , Antimaláricos/administración & dosificación , Antimaláricos/uso terapéutico , China , Cloroquina/administración & dosificación , Cloroquina/uso terapéutico , Ensayos Clínicos como Asunto , Humanos , Pandemias , Resultado del Tratamiento , Organización Mundial de la Salud